Meta-analysis finds immunotherapy plus chemotherapy improves outcomes in triple-negative breast cancer
New Combo Boosts Survival for Triple-Negative Breast Cancer
A meta-analysis of triple-negative breast cancer patients found that adding immunotherapy to chemotherapy improved pathological complete res…
Adding immune checkpoint inhibitors to chemotherapy improves survival and tumor response for triple-negative breast cancer patients.
Atezolizumab plus chemotherapy improved progression-free survival and patient-reported quality of life in metastatic triple-negative breast cancer
Adding atezolizumab to chemotherapy improved quality of life and survival in some patients with metastatic triple-negative breast cancer
This randomized trial evaluated adding atezolizumab to anthracycline-based chemotherapy versus chemotherapy plus placebo in patients with me…
Adding atezolizumab to chemotherapy improved quality of life, emotional functioning, and pain for patients with metastatic triple-negative b…
Neoadjuvant chemotherapy plus sintilimab improved response rates versus chemotherapy alone in 61 patients with triple-negative breast cancer
Combination therapy improved response rates in a small study of triple-negative breast cancer patients
This retrospective cohort study evaluated 61 patients with triple-negative breast cancer (TNBC) receiving neoadjuvant therapy at a single ce…
Adding the immunotherapy drug sintilimab to standard chemotherapy boosted response rates and slowed tumor growth in triple-negative breast c…
Pyroptosis-related gene signature predicts prognosis in triple-negative breast cancer patients
Can a gene signature predict survival for triple-negative breast cancer patients?
This observational cohort study analyzed data from TCGA and GEO databases, validated in an independent GEO cohort and 48 clinical samples, t…
A genetic warning system in triple-negative breast cancer tumors can predict which patients face a higher risk of the cancer returning.
PSMA PET/CT shows uptake in half of metastatic triple-negative breast cancer patients
Can a prostate cancer scan help treat aggressive breast cancer?
A prospective single-center study of 20 patients with progressive mTNBC found that 50% showed visual PSMA positivity on [Ga]Ga-PSMA-11 PET/C…
A prostate cancer scan found PSMA targets in half of aggressive breast cancer tumors, suggesting a new therapy option for patients when stan…
Research across Hormone Receptor-Positive Breast Cancer
Related studies from across the Hormone Receptor-Positive Breast Cancer family.
Datopotamab deruxtecan showed no overall survival benefit versus investigator's choice chemotherapy in metastatic HR-positive breast cancer.
Datopotamab deruxtecan extends life for advanced breast cancer patients
This Phase III randomized controlled trial evaluated datopotamab deruxtecan versus investigator's choice chemotherapy in patients with inope…
New drug datopotamab deruxtecan helps advanced breast cancer patients live longer and stay disease-free
Statins reduce recurrence risk 23% and mortality in 267,913 HR+ breast cancer patients with HR 0.77
Statins lower recurrence and death risk in hormone receptor-positive breast cancer
This systematic review and meta-analysis evaluated statin use versus non-use in 267,913 patients with hormone receptor-positive breast cance…
A massive analysis of over 267,000 patients shows statins reduce recurrence and death risk in hormone receptor-positive breast cancer.
Immunotherapy improves complete response but lacks overall response benefit in HR+ breast cancer
Immunotherapy shows mixed results for hormone-positive breast cancer patients
This systematic review and meta-analysis evaluated immunotherapy in patients with hormone receptor-positive and human epidermal growth facto…
A large analysis found immunotherapy did not improve overall survival but did increase side effects for hormone-positive breast cancer patie…
Trastuzumab deruxtecan improves PFS vs chemotherapy in HR-positive, HER2-low breast cancer
Trial shows T-DXd beats chemo for breast cancer
In a phase 3 RCT of 866 patients with HR-positive, HER2-low/-ultralow metastatic breast cancer after endocrine therapy, trastuzumab deruxtec…
A new drug, T-DXd, helps people with a common type of advanced breast cancer live longer without their disease getting worse.
Fulvestrant maintenance improves PFS versus capecitabine in HR+ HER2- metastatic breast cancer
Fulvestrant maintenance therapy significantly improves progression free survival compared to capecitabine in hormone receptor positive metastatic breast cancer patients
This randomized phase 3 trial in 210 patients with HR+ HER2- metastatic breast cancer compared fulvestrant to capecitabine after first-line …
In a study of 210 patients in China, fulvestrant helped keep cancer from growing longer than capecitabine. Fewer serious side effects occurr…
Review covers capecitabine and trastuzumab emtansine for triple-negative and HER2-positive breast cancer
Breast Cancer Chemo Is Getting Smarter and More Effective
This narrative review examines emerging therapies for women with breast cancer, including triple-negative and HER2-positive disease. The aut…
New blood tests and tumor markers are helping doctors choose the right chemo for breast cancer, reducing resistance and improving survival.
Radiofrequency ablation followed by radiation therapy shows noninferior 5-year recurrence-free survival compared to partial mastectomy in early stage breast cancer
Radiofrequency Ablation Offers Breast Cancer Patients a Less Invasive Option
This Phase 3 multicenter study evaluated 370 female patients with early stage breast cancer (Tis-T1, N0M0). Radiofrequency ablation followed…
A new five-year study proves that a needle-based treatment works just as well as removing part of the breast for early stage cancer.
CDK4/6 inhibitors plus endocrine therapy improve survival in advanced hormone receptor-positive breast cancer
CDK4/6 Inhibitors Boost Survival In Advanced Breast Cancer
This meta-analysis of 11 phase 3 trials involving 6035 patients demonstrates that CDK4/6 inhibitors combined with endocrine therapy signific…
New data shows adding CDK4/6 inhibitors to hormone therapy helps patients live longer with advanced breast cancer.
Gedatolisib plus fulvestrant with or without palbociclib improved progression-free survival versus fulvestrant monotherapy in advanced breast cancer
New Drug Combo Slashes Breast Cancer Progression Risk by 75%
This phase III randomized trial evaluated gedatolisib plus fulvestrant with or without palbociclib in patients with hormone receptor-positiv…
For patients with tough-to-treat advanced breast cancer, a new three-drug combination nearly quadrupled the time before the cancer started g…
Meta-analysis finds oral SERDs improve PFS over standard ET in HR+ HER2- ABC
New Drug Helps Some Breast Cancer Patients Live Longer
This systematic review and meta-analysis of 2,808 patients with HR+ HER2- advanced breast cancer found oral SERDs improved progression-free …
New oral pills help some advanced breast cancer patients live longer and fight back against drug resistance by blocking estrogen growth sign…
Adherence to 2021 ABS imaging recommendations in 148 male breast referrals at a UK hospital
Why Most Lumps in Men Don't Need a Mammogram, but Many Still Get One
This retrospective observational cohort study evaluated adherence to 2021 ABS imaging recommendations among 148 male patients referred to a …
A year-long UK clinic review found that most men referred for breast lumps had benign conditions, yet imaging was often done despite nationa…
Sequential paclitaxel-palbociclib showed no difference in ORR versus reverse sequence in ER+/HER2- breast cancer
New Test Predicts Who Needs Chemo in Breast Cancer
This randomized phase II trial evaluated sequential administration of paclitaxel and palbociclib with endocrine therapy in patients with ER+…
Doctors now have a way to spot patients who can skip chemo and go straight to safer hormone treatment.
Questions about Triple-Negative Breast Cancer
What are the new treatments for triple-negative and HER2-positive Breast Cancer?
New treatments for triple-negative breast cancer include chemo-immunotherapy (pembrolizumab plus platinum-based chemo) and potential NY-ESO-1 targeted therapies; for HER2-positive breast cancer, neoadjuvant targeted combinations and post-neoadjuvant trastuzumab emtansine are key
Full answer →Did the atezolizumab trial show better progression-free survival for metastatic triple-negative breast cancer patients?
Yes, the IMpassion130 trial showed atezolizumab plus nab-paclitaxel improved progression-free survival in PD-L1-positive metastatic triple-negative breast cancer, leading to FDA approval.
Full answer →Does taking capecitabine or trastuzumab emtansine treat triple-negative breast cancer effectively?
Capecitabine is not a standard treatment for triple-negative breast cancer (TNBC); trastuzumab emtansine targets HER2-positive cancer, not TNBC. Neither is considered effective for TNBC.
Full answer →What are the new immunotherapy options available to improve survival for triple-negative breast cancer patients?
New immunotherapy options for triple-negative breast cancer include immune checkpoint inhibitors like pembrolizumab combined with chemotherapy, which improve survival in PD-L1-positive advanced disease and early-stage patients.
Full answer →Does adding immune checkpoint inhibitors to chemotherapy improve survival for early-stage triple-negative breast cancer?
Yes, adding immune checkpoint inhibitors (like pembrolizumab) to chemotherapy improves event-free survival and pathologic complete response in early-stage triple-negative breast cancer, with some trials also showing overall survival benefit.
Full answer →